Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14076494 | 0.86 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL31435555 | 0.84 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAMAPTKDM4E | |
| SCHEMBL3091939 | 0.83 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL19320696 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL2927596 | 0.79 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL6999008 | 0.78 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL10330147 | 0.78 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL3756942 | 0.77 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL360530 | 0.76 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL21597594 | 0.75 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119215031-A | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-113645964-B | Arylaniline and heteroaryl aniline compounds for fetal treatment | 恩福莱克逊治疗有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-113660931-B | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-117551073-A | Thienylaniline compounds for the treatment of dermatological disorders | 恩福莱克逊治疗有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| CN-113660931-A | Arylaniline and heteroarylaniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113645964-A | Arylaniline and heteroarylaniline compounds for use in fetal marker therapy | 恩福莱克逊治疗有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113498340-A | Thienylaniline compounds for the treatment of skin diseases | 恩福莱克逊治疗有限公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3192794-A1 | SUSTAINED HIV PROTEASE INHIBITOR | Shionogi & Co., Ltd. (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204486-A1 | THIENYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, NAT1, BRAF | ALDH1A1 176/4885SMN1; SMN2 2951/4885LMNA 587/4885 |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | ALDH1A1 1050/4885SMN1; SMN2 2306/4885LMNA 496/4885 |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | ALDH1A1 4195/4885SMN1; SMN2 3538/4885LMNA 4384/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | ALDH1A1 3061/4885SMN1; SMN2 1864/4885LMNA 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.